ReviewCurrent atherosclerosis reports2015
Targeting PCSK9 for therapeutic gains.
Review in Current atherosclerosis reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.European heart journal · 2017 · on this mapTrial
- Are RNA Therapies a Solid Foundation or a Frontier Yet to Be Conquered?International journal of molecular sciences · 2026Review
- Current usage of inclisiran for cardiovascular diseases: overview of current clinical trials.Frontiers in pharmacology · 2025Review
- Review
- Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?Ecancermedicalscience · 2022Review
- Article
- PCSK9: From Basic Science Discoveries to Clinical Trials.Circulation research · 2018Review
- Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering.Nature reviews. Cardiology · 2017Article
- PCSK9 and Atherosclerosis - Lipids and Beyond.Journal of atherosclerosis and thrombosis · 2017Review
- Selective stalling of human translation through small-molecule engagement of the ribosome nascent chain.PLoS biology · 2017Article
- Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease.F1000Research · 2017Review
- The role of HDL in plaque stabilization and regression: basic mechanisms and clinical implications.Coronary artery disease · 2016Review
- Endocytic adaptors Arh and Dab2 control homeostasis of circulatory cholesterol.Journal of lipid research · 2016Article
- Review
- New developments in atherosclerosis: clinical potential of PCSK9 inhibition.Vascular health and risk management · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Even though it is only a little over a decade from the discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) as a plasma protein that associates with both hypercholesterolemia and low cholesterol syndromes, a rich literature has developed describing its unique physiology and the impact of antagonism of this molecule on cholesterol metabolism for therapeutic purposes. Indeed, the PCSK9 story is unfolding rapidly, with many answers and more questions. This review summarizes the most recent data from phase II/III clinical trials of PCSK9 inhibition with the three leading antibodies, highlights the clinical significance of the ongoing studies, and suggests future areas of investigation based on recent basic science discoveries on the physiology of PCSK9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.